ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Mortality Among Patients With Invasive Group A Streptococcal Infections Caused by the M1UK Lineage: A Retrospective Cohort Study in England and Wales.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predominance of M1European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- M1UK LineageInfection & chemotherapy · 2026Article
- Evaluating the use of whole-genome sequencing and SangerJournal of medical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe M1UK sublineage of Streptococcus pyogenes has driven recent post-pandemic surges in invasive group A streptococcal (iGAS) disease. We assessed case fatality rate (CFR) among patients with emm1 iGAS in England and Wales, and then compared outcomes associated with M1UK and ancestral emm1 lineages.
methodsWe linked emm1 iGAS cases (December 2009-July 2022) with demographic and mortality records. Lineage was determined for isolates collected in 2010, 2013-2016, and 2020 via whole-genome sequencing or allele-specific PCR. Seven- and 30-day all-cause CFRs were estimated. Univariate and multivariate models assessed the association between lineage and risk of death.
resultsAmong 4952 emm1 iGAS cases, lineage was assigned to 1356. The 30-day CFR was 24.4% for M1UK, 22.3% for M1global, 10.5% for M123SNP, and 10.3% for M113SNP. After adjustment for age and sex, lineage was not a significant predictor of 7- or 30-day mortality. Survival analysis showed rapid progression to death in both M1UK and M1global cases: 63.7% of deaths occurred within 1 day of diagnostic sampling. Among children under 15 years, 56.3% of fatal cases died before sampling, and 95.6% within 1 day of sampling.
conclusionsMortality did not differ significantly between M1UK and M1global lineages, but more studies are required. Overall mortality from emm1 S. pyogenes remains strikingly high. The rapid time to death underscores the need for preventive measures and rapid diagnostic tools that act prior to culture-based confirmation, and highlights challenges for clinical trial design in iGAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.